The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris.
Nathan P WiederholdLaura K NajvarRosie JaramilloMarcos OlivoHoja PattersonApril ConnellYoshiko FukudaJunichi MitsuyamaGabriel CatanoThomas F PattersonPublished in: Antimicrobial agents and chemotherapy (2020)
The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).